Despite the limitations of the study due to its exploratory/preliminary nature and modest recruiting, our results succeeded in associating total circulating MMP-1 levels with prostatic malignancy in a real outpatient setting, particularly prevalent in metabolic disorders [35] and comorbidities [36] (as expected in developing countries) and with the prostate condition of each patient confirmed according to the best possible clinical practice. Here, MMP1 is linked to Other metabolic disease.